巨子生物周四(17日)早上公布，配售最多3,500万股股份，相当于扩大后股本3.27%;配售价66.65港元，较上交易日(16日)收市价折让9.5%。花旗发布研报称，鉴于较大的折让，预期短期内该股的股价将会承压。尽管如此，巨子生物(02367)的盈利前景依然稳健，故维持该股的“买入”评级，目标价78.1港元。巨子生物周四(17日)早上公布，配售最多3,500万股股份，相当于扩大后股本3.27%;配...
Source Link巨子生物周四(17日)早上公布，配售最多3,500万股股份，相当于扩大后股本3.27%;配售价66.65港元，较上交易日(16日)收市价折让9.5%。花旗发布研报称，鉴于较大的折让，预期短期内该股的股价将会承压。尽管如此，巨子生物(02367)的盈利前景依然稳健，故维持该股的“买入”评级，目标价78.1港元。巨子生物周四(17日)早上公布，配售最多3,500万股股份，相当于扩大后股本3.27%;配...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.